These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38793722)
1. High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread, Often Unrecognized, Contact with the Virus. Swadźba J; Panek A; Wąsowicz P; Anyszek T; Martin E Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793722 [TBL] [Abstract][Full Text] [Related]
2. The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration. Swadźba J; Anyszek T; Panek A; Chojęta A; Piotrowska-Mietelska A; Martin E Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851157 [TBL] [Abstract][Full Text] [Related]
3. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
4. Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination. Swadźba J; Anyszek T; Panek A; Martin E Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835298 [TBL] [Abstract][Full Text] [Related]
5. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals. Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764 [TBL] [Abstract][Full Text] [Related]
6. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination. Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836 [TBL] [Abstract][Full Text] [Related]
7. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S Front Immunol; 2022; 13():876533. PubMed ID: 35711413 [TBL] [Abstract][Full Text] [Related]
8. Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens. Culebras E; Martínez M; Novella C; León JM; Marcos E; Delgado-Iribarren A; Ríos E Front Cell Infect Microbiol; 2024; 14():1370859. PubMed ID: 38572317 [TBL] [Abstract][Full Text] [Related]
9. [Monitoring of anti-SARS-CoV-2 IgG antibody immune responses in two cohorts of Hungarian healthcare workers following infection or immunization]. Gervain J; Szabóné Bartha K; Bakiné Hodovánszky E; Kadlecsik L; Herczeg R; Gyenesei A; Simon J Orv Hetil; 2022 Mar; 163(12):455-462. PubMed ID: 35306478 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study. Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898 [TBL] [Abstract][Full Text] [Related]
12. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers. Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662 [TBL] [Abstract][Full Text] [Related]
13. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections. Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831 [TBL] [Abstract][Full Text] [Related]
14. [COVID-19 infections and effectiveness of the vaccination among healthcare workers]. Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547 [TBL] [Abstract][Full Text] [Related]
15. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery. Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127 [TBL] [Abstract][Full Text] [Related]
16. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic. Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266 [TBL] [Abstract][Full Text] [Related]
17. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577 [TBL] [Abstract][Full Text] [Related]
18. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed? Stellini R; Gianello R; Gomarasca W Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649 [TBL] [Abstract][Full Text] [Related]
19. Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination? van den Hoogen LL; Smits G; van Hagen CCE; Wong D; Vos ERA; van Boven M; de Melker HE; van Vliet J; Kuijer M; Woudstra L; Wijmenga-Monsuur AJ; GeurtsvanKessel CH; Stoof SP; Reukers D; Wijsman LA; Meijer A; Reusken CBEM; Rots NY; van der Klis FRM; van Binnendijk RS; den Hartog G Vaccine; 2022 Apr; 40(15):2251-2257. PubMed ID: 35287986 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Hayer J; Urlaub E Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]